Skip to content
Companies

Quanta Therapeutics

Oral KRAS G12D and G12V inhibitors for cancer

Raised to date

$76.2M

of $89.1M offered across 1 Form D filing

Still open
$12.9M
Investors
17
Last filed
Jun 24, 2026

About

Quanta Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule allosteric inhibitors of RAS-driven cancers. It targets KRAS mutations beyond G12C — notably G12D and G12V — which together account for a large share of RAS-mutant tumors. Its lead candidate QTX3034 is in Phase 1 dose expansion in pancreatic, colorectal and endometrial cancers, both as monotherapy and in combination with cetuximab and chemotherapy. The company operates from South San Francisco, CA with an additional site in Radnor, PA.

A proprietary Second Harmonic Generation platform that measures subtle protein conformational changes at high throughput, enabling allosteric drug discovery against RAS signaling complexes previously considered undruggable.

Funding

  • EquityFiled Jun 24, 2026Form D/A
    $76.2M/ $89.1M

Product

QTX3034

Clinical-stage oncology drug candidate

An oral, G12D-preferring multi-KRAS allosteric inhibitor in Phase 1 dose expansion, studied as monotherapy and in combination with cetuximab and chemotherapy in pancreatic, colorectal and endometrial cancers.

  • Oral small molecule
  • Allosteric, conformational blockade mechanism
  • G12D-preferring with multi-KRAS activity

Built for

Oncologists and patients with RAS-driven solid tumors — pancreatic, colorectal and endometrial cancer — plus pharmaceutical partners for RAS programs

People on file